Covid 19 Research using Clinical Trials (Home Page)
MCN (Methylene blue, vitamin C, N-acetyl cysteine)Wiki
Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation
Correlated Drug Terms (1)
Correlated MeSH Terms (3)
There is one clinical trial.
Clinical Trials
The severe acute respiratory syndrome caused by COVID-19 is now a global catastrophic event.
Currently there is no approved drug or vaccine for the disease. Methylene blue (MB, oxidized
form, blue color) has been used in many different areas of clinical medicine, ranging from
malaria to orthopedics. Leucomethylene Blue (reduced form of MB, colorless) may be applied
for the treatment of COVID-19 according to the scientific evidences.
NCT04370288 Covid-19 Drug: MCN (Methylene blue, vitamin C, N-acetyl cysteine)
Primary Outcomes
Description: All patient will be assess for changes in disease severity.
Measure: Proportion of patients remaining free of need for mechanical ventilation in both groups
Time: Day 7
Secondary Outcomes
Measure: Mortality rate in both groups Time: Day 28
Measure: Improvement in Pa02/Fi02 ratio in both groups Time: Day 2
Measure: Duration of hospital stay in both group. Time: Day 28
Measure: Duration of Intensive Care Unit stay in both groups Time: Day 28
Measure: Days free of dialysis in both groups Time: Day 28
Measure: C-reactive proteins Time: 3-5 Days
Measure: WBC Count Time: 3-5 Days
No related HPO nodes (Using clinical trials)